echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Don't be too happy! How to treat the abolition of low-cost drugs in a correct way?

    Don't be too happy! How to treat the abolition of low-cost drugs in a correct way?

    • Last Update: 2019-12-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, in response to the proposal No 0177 of the second session of the 13th National Committee of the CPPCC, the state health insurance bureau clearly stated that in the future, it will eliminate the upper limit of the current daily average cost of low-cost drugs, establish a monitoring and early warning platform for the use of drugs in short supply as soon as possible, strengthen the production of fixed-point orders for clinically necessary drugs, and form a joint force of low-cost drug price supervision So, recently, the industry exclaimed: low-cost medicine has been abolished, and the spring of low-cost medicine has come! The author also wants to exclaim: the abolition of low-cost drugs should be treated correctly Don't be happy too early On November 26, 2019, the State Health Insurance Bureau officially issued the opinions on the current drug price management, which is rich in content, especially the matters about low-cost drugs This article describes how to implement the policies of linking up the Internet and purchasing the drugs in short supply Local medical security departments should strengthen the guidance of centralized purchase and use of short drugs, and effectively implement the policy of direct online purchase of short drugs For the varieties listed in the list of short drugs in the national and provincial meeting linkage mechanism Office of short drug supply guarantee work, operators are allowed to quote independently and directly hang up the network, and medical institutions are allowed to purchase according to the price of hanging up the network or negotiate with the operators for further purchase If there is no enterprise on the provincial drug centralized purchase platform or the short drugs are not listed in the provincial centralized purchase directory, the medical institutions are allowed to record and purchase independently according to the regulations The medical insurance fund shall timely pay for the medicines in short supply that belong to the medical insurance catalogue according to the regulations The medical security department will no longer make and publish the list of low-cost drugs according to the price or cost of drugs After reading this article, many friends think that the era of low-cost medicine is officially over The author believes that, in terms of literal understanding, the part of low-cost drugs is mainly related to the lack of drugs hanging on the Internet from the perspective of top-level design In that year, when the list of low-cost drugs was made, it showed gradual respect for the market mechanism and reversed the past practice of only reducing drugs but not increasing them The core idea of the low-cost drug list in that year is also in line with the law of market demand, that is, to use price to regulate market supply and demand, and to achieve the purpose of regulation by playing the regulatory role of the market itself From such a perspective, we will look back to the original opinion just issued: "based on the current drug price policy, adhere to the decisive role of the market in resource allocation, better play the role of the government, and continue to improve the market-oriented drug price formation mechanism around the overall development direction of the medical security system in the new era." From this point of view, the idea of price management after the establishment of the medical insurance bureau is basically the same as that of the later stage of price management of the national development and Reform Commission If the market can effectively adjust, let the market adjust itself At present, the market competition has sufficient volume procurement and insufficient online price support In fact, it is not very important to have or not to have a list of low-cost drugs The introduction of market self-regulation mechanism has gradually matured, which is why the health insurance bureau put low-cost drugs in the shortage of drugs In 2014, when the national development and Reform Commission formulated the low-cost drug policy, although it gave the advantages of direct Internet access at that time, its status has been relatively awkward At that time, the basic drug catalog issued by the state has been supported by clear policies, including the proportion of primary hospitals, the proportion of secondary and tertiary hospitals, etc., but it has not been in place in terms of security Therefore, the background of the introduction of low-cost drugs at that time was mainly to ensure the use of basic drugs The emergence of low-cost drugs list is more like a supplementary means of basic drugs, and a strategic consideration considering the continuity and stability of "basic, strong grass-roots and mechanism building" Since 2015, with the promulgation of No.7 document and drug price reform, in the new round of classified procurement cycle, the effect of low-cost drugs has been limited: some provincial centralized bidding procurement for low-cost drugs still implements the national lowest price online, price linkage, and even takes the linked price as the reference price, and medical institutions and enterprises negotiate the price As a result, there are many problems such as the disappearance of low-cost drugs in some regions, the effect of price reduction is not obvious, and some varieties involve monopoly At the same time, the mechanism of drug use in public hospitals was still distorted and abnormal at that time, which had formed a rule of drug use that was divorced from pharmacoeconomics and derailed to the emotional marketing of color change At the same time, the system level was lack of restrictive measures for clinical overtreatment In this context, some low-cost drugs with lower profits are disappearing in medical institutions, while some low-cost drugs with higher profits are flourishing Until 2018, after the launch of the national 4 + 7 project, with the expansion of joint mining and the coming of the second batch of national joint mining, all parts of the country have a new understanding of volume procurement, and the term low-cost drugs is more closely related to the shortage of drugs In other words, in the new situation, the drug management is controlled by the market and the administration If the price is low, it should be raised upward If the price is high, it should be pressed downward The establishment of the monitoring and early warning mechanism for abnormal changes in price supply is not only to prevent price hikes, but also to prevent prices from being suppressed too low, resulting in the inability to supply Therefore, from this perspective Look, it's actually wearing a raincoat and an umbrella to explicitly propose to abolish low-cost drugs Since waste and not waste are the same, since not waste can play a certain role, then why waste?! In the future, no list will be made Therefore, in the future, we will cancel the upper limit of the daily average cost of low-cost drugs As for the low-cost drugs policies in various regions, they have actually been integrated into the actual operation of volume purchase as an effective price control means to balance However, this does not mean that the upper limit of the daily average cost of low-cost drugs will be released, and enterprises will be allowed to adjust their prices (except for the shortage of varieties) Without the identity protection of low-cost drugs, it means that the original low-cost drugs, together with other fully competitive and insufficiently competitive varieties, will be carried into the flood of volume procurement, cataloguing, qualification, price and market So, is this cancellation of daily average cost a good news or a new challenge for low-cost drugs? It goes without saying In the context of more and more subdivisions of national drug use, on the basis of continuous in-depth purchasing with volume, there is no need for the existence of low-cost drugs, but low-cost drugs are not as simple as 1 + 1 = 2, but whether the result is equal to 3 or 1, enterprises should have a clear understanding and judgment 37 statement: This article only represents the author and does not represent the position of yaozhi.com You are welcome to communicate and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.